Initial results announced on the combination of the Allurion balloon with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence – Allurion Technologies
Allurion Technologies, Inc. announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with… read more.
